Edgewise Therapeutics (EWTX) Total Non-Current Liabilities (2021 - 2022)
Edgewise Therapeutics (EWTX) reported Total Non-Current Liabilities of $10.9 million for Q2 2022, down 11.06% sequentially from $12.2 million in Q1 2022.
Edgewise Therapeutics (EWTX) Total Non-Current Liabilities (2021 - 2022) Analysis & Trends
Edgewise Therapeutics (EWTX) has 2 years of Total Non-Current Liabilities data on file, last reported at $10.9 million in Q2 2022.
- For the quarter ending Q2 2022, Total Non-Current Liabilities changed N/A year-over-year to $10.9 million; the trailing twelve-month figure through Jun 2022 stood at $10.9 million (changed N/A YoY), and the FY2021 full-year result was $10.5 million, changed N/A from the prior year.
- Total Non-Current Liabilities declined to $10.9 million in Q2 2022, from $12.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $12.2 million in Q1 2022 to a low of $8.8 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Edgewise Therapeutics | 4.21 Bn | 4.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 10.85 Mn |
| Mar 31, 2022 | 12.20 Mn |
| Dec 31, 2021 | 10.52 Mn |
| Sep 30, 2021 | 8.75 Mn |